Prohost BiotechResearch Platform

Home Articles Trick or TradeCan Cassava Sciences Resurrect When Simufilam is Used to Treat Seizures Related to Rare Neurodevelopmental Disorders Instead of Alzheimer’s Disease?

Trick or Trade

Premium

Can Cassava Sciences Resurrect When Simufilam is Used to Treat Seizures Related to Rare Neurodevelopmental Disorders Instead of Alzheimer’s Disease?

Cassava Sciences in the NEWS Cassava Sciences, Inc. ( SAVA ) announced that it entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive lic...

P

Prohost Biotech

February 28, 2025

1 min read

1

0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles

Expert analysis

Research reports

Tags

Cassava Sciences (SAVA)

Comments (0)

Please sign in to join the discussion

Related Articles

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech BioNTech ( BNTX ) announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in patients with HER2-expressing, advanced endometrial cancer whos...

Prohost Biotech

Apr 17, 2026

Zymeworks Inc Question and Answer

Zymeworks Inc Q & A Q: What’s the story about Zymeworks entering into a deal with Royalty Pharma? A: Zymeworks and Royalty Pharma have already entered into $250 Million Royalty-Backed Note Financing....

Prohost Biotech

Mar 12, 2026

Milestone Receives FDA Approval of CARDAMYST™ as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia

Milestone in the NEWS MONTREAL and CHARLOTTE, Milestone ® ( MIST ) announced that the U.S. FDA approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for...

Prohost Biotech

Dec 16, 2025